COMMUNIQUÉS West-GlobeNewswire

Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
13/03/2026
MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN) 1 , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian [...]
Novonesis issues EUR 1.7 billion senior unsecured notes
13/03/2026
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly [...]
Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor
13/03/2026
MOORESVILLE, N.C., March 13, 2026 (GLOBE NEWSWIRE) -- The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box , a monthly drop of hand-selected flower and pre-rolls delivered to your door, including [...]
IBA Notice of Full Year 2025 Results and Conference Call
13/03/2026
FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, [...]
IBA : Publication des résultats annuels 2025 et conférence web
13/03/2026
La conférence sur les résultats de l’exercice 2025 aura lieu le vendredi 27 mars 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 13 mars 2026 - IBA (Ion Beam Applications S.A le leader mondial des [...]
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
13/03/2026
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
13/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
GlycoPezil Supplement Claims Evaluated - Complete Investigation of the Blood Sugar Support Ingredients
12/03/2026
A 2026 consumer research report examining GlycoPezil's ingredient research references, proprietary blend structure, pricing transparency, and verification considerations for adults researching blood sugar support [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
12/03/2026
TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to patients, [...]
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
12/03/2026
Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q4 and year end [...]
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
12/03/2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
12/03/2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Voting Rights and Shares Capital of the Company
12/03/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 12, 2026 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
12/03/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 12 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
12/03/2026
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading access on Nasdaq [...]
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
12/03/2026
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for [...]

Pages